How to Buy Cencora Stock
Cencora Inc
Cencora is a medical distribution company located in Pennsylvania, United States, which is part of the Healthcare sector, and is traded under the ticker COR on the NYSE exchange.
Cencora stock last closed at $261.08, up 2.12% from the previous day, and has decreased 8% in one year. It has underperformed other stocks in the Medical Distribution industry by 0.13 percentage points. Cencora stock is currently +6.64% from its 52-week low of $244.82, and -30.85% from its 52-week high of $377.54.
There are currently 194.56M shares of COR outstanding. The market cap of COR is $50.80B. In the past 24 hours, 2.67M COR shares were traded.
How to Buy Cencora Stock
Wondering how to invest in Cencora stock? Here's how.
- Decide where to buy Cencora stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you figure out where to buy Cencora stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your payment method and add your details.
- Evaluate Cencora stock: The Cencora ticker symbol is COR. Is Cencora stock a good investment? Should you buy shares of COR? How do COR's underlying business fundamentals look? Do top analysts think Cencora is a good buy? Why has COR's stock price moved recently? (Hint: Our stock market analysis website can help you understand if COR is a good stock to buy).
- Make your COR buy order: Decide if you will purchase COR shares at the current market price or use a limit order to purchase COR stock at a specific price.
- Keep an eye on your COR investment: Create a watchlist to the latest updates on your new investment in Cencora stock.
Step 1: Decide where to buy Cencora stock
You need a brokerage account to access the NYSE market and buy COR shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the right brokerage, the next step is to fill out some personal info so you are able to invest in COR today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create a new trading account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have created your account on the highest rated app to buy and sell stocks, you can securely and quickly fund your account:
Watch the video below if you need help depositing funds into your brokerage account.
Step 4: Evaluate Cencora stock
After you have figured out the best place to buy Cencora stock, it's absolutely critical to evaluate their stock before you buy, so you can comprehend the risk as well as the upside.
Cencora Metrics
COR Due Diligence Checks
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis.
You can view all of the due diligence checks on COR's stock page.
What is the fair value of COR stock?
You can use a variety of different financial metrics, analyses, models, and charts to gauge COR's true value.
Using relative valuations measures:
- COR may be undervalued based on its P/E ratio of 19.9x, relative to Medical Distribution industry P/E ratio of 21.12x
- COR may be undervalued based on its P/B ratio of 14.95x, relative to Medical Distribution industry P/B ratio of 137.03x
- COR may be overvalued based on its PEG ratio of 1.07x
You can access more valuation research on COR's stock here.
COR Financial Overview
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the COR balance sheet.
- COR earnings of $3.88B is not enough to cover its interest payments.
- Total COR debt is lower than 5 years ago, relative to shareholder equity.
- COR profit margin has gone up from 0.5% to 0.8% in the past year.
Failed Financial Due Diligence Checks:
- COR has a relatively high debt to equity ratio of 22.98.
- COR's operating cash flow of $2.28B allows it to safely service it's debt of $12.39B.
- There are more short-term liabilities than short-term assets on the COR balance sheet.
Do Wall Street analysts think it's a good time to buy COR stock
Out of 11 Equities analysts who monitor COR, the consensus analyst rating on Cencora is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent COR Analyst Ratings
Lisa Gill, a top 21% analyst from JP Morgan maintains COR with a strong buy rating and raises their COR price target from $417.00 to $419.00, on Feb 10, 2026.
JP Morgan's Lisa Gill raised their price target on Cencora (NYSE: COR) by 0.5% from $417 to $419 on 2026/02/10. The analyst maintained their Strong Buy rating on the stock.
Cencora reported its Q1 2026 earnings.
Raising their price target, Gill attributed their price target hike to the stength of the quarter's results and management FY 2026 guidance.
Earnings Report
For Q1 2026, Cencora reported:
- EPS of $4.08, which beat the Zacks Consensus Estimate of $4.07 and Q1 2025 by 9.4%.
- Revenue of $85.93B, which met the Zacks Consensus Estimate and was up 5.5% Y/Y.
For FY 2026, management guided:
- EPS of $17.45 to $17.75.
- 7% to 9% Y/Y revenue growth.
President & CEO Robert P. Mauch commented: “Cencora began fiscal 2026 by delivering strong financial performance and advancing our strategy through the acquisition of OneOncology.
“Our ownership of OneOncology cements our specialty MSO footprint and deepens our partnership with physicians leading in cancer care.
“As we continue to advance our leadership in specialty and execute our pharmaceutical-centric strategy, we are well-positioned to drive continued value for all our stakeholders and deliver on our purpose.”
Stephen Baxter, a top 17% analyst from Wells Fargo maintains COR with a strong buy rating and raises their COR price target from $405.00 to $429.00, on Feb 10, 2026.
Erin Wright, a top 6% analyst from Morgan Stanley upgrades COR to a strong buy rating and raises their COR price target from $361.00 to $400.00, on Jan 29, 2026.
Brian Tanquilut, a top 18% analyst from Jefferies upgrades COR to a strong buy rating and raises their COR price target from $330.00 to $440.00, on Jan 22, 2026.
Michael Funk, a bottom 5% analyst from Bank of America maintains COR with a hold rating and lowers their COR price target from $380.00 to $360.00, on Jan 5, 2026.
You can dig deeper into what analysts are projecting on the Cencora stock forecast page.
Metrics for Advanced COR Traders
How is COR performing as a company?
Last year, COR earnings were $2.55B. During the last four year, COR's earnings have gone up by 12.13% per year. This was slower than the Medical Distribution industry average of 29.36%.
Last year, COR revenue was $328.68B. During the past five year, COR's revenue has grown by 10.86% per year. This was faster than the Medical Distribution industry average of 10.05%.
You can analyze COR's earnings and revenue performance here.
Are COR executives and large shareholders buying or selling the stock?
In the past 12 months, insiders at COR have sold more shares than they have bought.
Ellen Cooper, Director of COR, was the latest COR insider to buy. They bought $30,096.00 worth of COR shares on May 1, 2026.
Learn more about who owns COR stock here.
Can I get consistent income from COR stock?
Cencora pays a dividend of 0.88%, compared to the Medical Distribution industry's average dividend yield of 0.81%. If you owned $1,000 worth of COR stock, you would have received $8.81 in the past 12 months.
Cencora dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Cencora dividend yield and history here.
COR Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your COR buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your COR investment
Now that you own some COR stock, you'll want to keep up with your new company.
Start a watchlist to monitor your COR stock.
COR Feed
How to Buy Stock in Cencora
To summarize, here are the 6 steps to buy Cencora stock:
- Decide where to buy Cencora stock
- Sign up for your brokerage account
- Fund your investment account
- Evaluate Cencora stock
- Make your COR buy order
- Keep an eye on your COR investment
If you require a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Cencora, add COR to your watchlist by clicking the button below.
More Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.